BDO has provided buy-side CDD on the acquisition of FutureMeds by Phoenix Equity Partners

BDO has provided buy-side CDD to Phoenix Equity Partners in relation to its investment in FutureMeds, a leading pan-European Site Management Organisation providing patient recruitment and clinical trial management services.

FutureMeds, founded in 2019, has grown into one of Europe's largest Site Management Organisations operating 28 clinical sites across seven different countries. It is expected to see significant growth going forward, both from expansion of its decentralised clinical trial (‘DCT’) capabilities, and from establishing new sites in other European countries.   

The BDO CDD team provided support to validate FutureMeds's market size, its strong customer relationships and competitive differentiators, as well as identifying key levers for its continued future growth.

We appointed BDO to provide buy-side CDD in relation to our investment in FutureMeds. The BDO team were a huge help throughout the transaction, putting a lot of effort in to deliver over a very short timeframe. The insights that BDO provided to us were hugely valuable, both in terms of building our internal conviction on the opportunity and also, in shaping our views on the strengths of FutureMeds and the markets it operates in. BDO’s work will continue to be a useful reference point for us, as we and FutureMeds look to develop our post-acquisition strategy. A big thank you to BDO!

Matthew Mellon, Investment Manager, Phoenix Equity Partners

The BDO project team included: 
Gurpal Ahluwalia, David Wentholt, Dodi Behiri, Sam Harraden, James Day, Andrew Goodluck, Charles Jervis